Antiresorptive agents and osteoclast apoptosis

Paula H. Stern*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Antiresorptive agents have proven to be effective therapies for the treatment of bone diseases associated with excessive osteoclast activity. Decreased osteoclast formation, inhibition of osteoclast actions, and reduced osteoclast survival represent mechanisms by which antiresorptive agents could act. The goals of this article are to present the evidence that antiresorptive agents can decrease osteoclast survival through apoptosis, to review the mechanisms by which they are thought to activate the apoptotic process, and to consider whether the actions on apoptosis fully account for the antiresorptive effects. As background, the apoptotic process will be briefly summarized together with the evidence that factors that promote osteoclast survival affect steps in the process. Following this, therapeutic agents that are both antiresorptive and can stimulate osteoclast apoptosis will be discussed. Other bone therapeutic agents that are either antiresorptive or apoptotic, but not both, will be described. Finally, newer antiresorptive compounds that elicit apoptosis and could represent potential therapeutic agents will be noted.

Original languageEnglish (US)
Pages (from-to)1087-1096
Number of pages10
JournalJournal of Cellular Biochemistry
Issue number5
StatePublished - Aug 1 2007


  • Apoptosis
  • Bone resorption
  • Osteoclast

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Antiresorptive agents and osteoclast apoptosis'. Together they form a unique fingerprint.

Cite this